A Study of MabThera/Rituxan (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis and Inadequate Response to DMARD Therapy

NCT02006706 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

DRUG: rituximab [MabThera/Rituxan]
DRUG: methotrexate
DRUG: methylprednisolone

Sponsor

Hoffmann-La Roche